1. Scannell JW, Blanckley A, Boldon H, et al. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 2012; 11: 191–200.
2. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE FOR GOOD CLINICAL PRACTICE E6 (R1). https://www.pmda.go.jp/files/000156725.pdf
3. Funning S, Grahnén A, Eriksson K, et al. Quality assurance within the scope of good clinical practice (GCP) - what is the cost of GCP-related activities? a survey within the Swedish Association of the Pharmaceutical Industry (LIF)’s members. Qual Assur J 2009; 12: 3–7.
4. 厚生労働省. 人を対象とする医学系研究に関する倫理指針ガイダンス. https://www.mhlw.go.jp/file/06-Seisakujouhou-10600000- Daijinkanboukouseikagakuka/0000166072.pdf
5. 厚生労働省. 臨床研究法(平成二十九年法律第十六号). https://www.mhlw.go.jp/file/06-Seisakujouhou-10800000- Iseikyoku/0000163413.pdf
6. Sheetz N, Wilson B, Benedict J, et al. Evaluating source data verification as a quality control measure in clinical trials. Ther Innov Regul Sci 2014; 48: 671–680.
7. Andersen JR, Byrjalsen I, Bihlet A, et al. Impact of source data verification on data quality in clinical trials: an empirical post hoc analysis of three phase 3 randomized clinical trials. Br J Clin Pharmacol 2015; 79: 660-668.
8. Mitchel JT, Kim YJ, Choi J, et al. Evaluation of data entry errors and data changes to an electronic data capture clinical trial database. Drug Inf J 2011; 45: 421–430.
9. Tudur Smith C, Stocken DD, Dunn J, et al. The value of source data verification in a cancer clinical trial. PLoS ONE 2012; 7: e51623.
10. Tantsyura V, Dunn IM, Fendt K, et al. Risk-based monitoring: a closer statistical look at source document verification, queries, study size effects, and data quality. Ther Innov Regul Sci 2015; 49: 903–910.
11. US Food and Drug Administration. Guidance for industry oversight of clinical investigations – a risk-based approach to monitoring, https://www.fda.gov/media/116754/download.
12. European Medicines Agency. Reflection paper on risk based quality management in clinical trials, https://www.ema.europa.eu/en/documents/scientific-guideline/reflection- paper-risk-based-quality-management-clinical-trials_en.pdf.
13. Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. Basic rules of the risk-based approach to monitoring clinical trials, https://www.pmda.go.jp/files/000215858.pdf.
14. TransCelerate BioPharma Inc. Position paper: risk-based monitoring methodology, http://www.transceleratebiopharmainc.com/wp- content/uploads/2016/01/TransCelerate-RBM-Position-Paper-FINAL- 30MAY2013.pdf.pdf.
15. US Food and Drug Administration. Integrated Addendum to ICH E6 (R1): Guideline for Good Clinical Practice E6 (R2), https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf.
16. Olsen R, Bihlet AR, Kalakou F, et al. The impact of clinical trial monitoring approaches on data integrity and cost—a review of current literature. Eur J Clin Pharmacol 2016; 72: 339-412.
17. Nielsen E, Hyder DA, Deng C. A data-driven approach to risk-based source data verification. Ther Innov Regul Sci 2014; 48: 173–180.
18. Tantsyura V, Dunn IMC, Waters J, et al. Extended risk-based monitoring model, on-demand query-driven source data verification, and their economic impact on clinical trial operations. Ther Innov Regul Sci 2016; 50: 115–122.
19. Timmermans C, Venet D, Burzykowski T. Data-driven risk identification in phase III clinical trials using central statistical monitoring. Int J Clin Oncol 2016; 21: 38–45.
20. Bakobaki JM, Rauchenberger M, Joffe N, et al. The potential for central monitoring techniques to replace on-site monitoring: findings from an international multi-centre clinical trial. Clin Trials 2012; 9: 257–264.
21. Lindblad AS, Manukyan Z, Purohit-Sheth T, et al. Central site monitoring: Results from a test of accuracy in identifying trials and sites failing Food and Drug Administration inspection. Clin Trials 2014; 11: 205–217.
22. Brosteanu O, Schwarz G, Houben P, et al. Risk-adapted monitoring is not inferior to extensive on-site monitoring: results of the ADAMON cluster- randomized study. Clin Trials 2017; 14: 584–596.
23. Stenning SP, Cragg WJ, Joffe N, et al. Triggered or routine site monitoring visits for randomised controlled trials: results of TEMPER, a prospective, matched-pair study. Clin Trials 2018; 15: 600–609.
24. Hurley C, Shiely F, Power J, et al. Risk based monitoring (RBM) tools for clinical trials: a systematic review. Contemp Clin Trials 2016; 51: 15-27.
25. Kumar PP, Dalal J, Jadhav MP. Risk based monitoring (RBM): a global study focusing on perception and merits among clinical investigational sites. Contemp Clin Trials Commun 2016; 4: 155-160.
26. Caroline H, Carol S, Mike C, et al. Perceived barriers and facilitators to risk-based monitoring in academic-led clinical trials: a mixed methods study. Trials 2017; 18: 423.
27. Houston L, Probst Y, Yu P, et al. Exploring data quality management within clinical trials. Appl Clin Inform 2018; 9: 72–81.
28. Mealer M, Kittelson J, Thompson BT, et al. Remote source document verification in two national clinical trials networks: a pilot study. PLoS One 2013; 8: e81890.
29. Weston W, Smedley J, Bennett A, et al. The cooking and pneumonia study (CAPS) in Malawi: implementation of remote source data verification. PLoS One 2016; 11: e0155966.
30. Uren SC, Kirkman MB, Dalton BS, et al. Reducing clinical trial monitoring resource allocation and costs through remote access to electronic medical records. J Oncol Pract 2013; 9: e13–e16.
31. 日本製薬工業協会. モニタリングの効率化に関する提言. http://www.jpma.or.jp/medicine/shinyaku/tiken/allotment/pdf/monitoring_0 2_01.pdf
32. Madhuri P. Remote Site Monitoring: The Future of Clinical Research. Curr Trends Biomedical Eng & Biosci. 2017; 9: 555771.
33. De S. Hybrid approaches to clinical trial monitoring: practical alternatives to 100% source data verification. Perspect Clin Res 2011; 2: 100–104.
34. TransCelerate BioPharma Inc. Risk assessment and categorization tool (RACT), https://www.transceleratebiopharmainc.com/assets/risk-based- monitoring-solutions/.
35. Favalli G VJ, Vantongelen K, Renard J, et al. Quality control in multicentric clinical trials. An experience of the EORTC Gynecological Cancer Cooperative Group. Eur J Cancer 2000; 36: 1125–1133.
36. Wilson EB. Probable Inference, the Law of Succession, and Statistical Inference. J Am Stat Assoc 1927; 22: 209-12.
37. Jeong IS, Jeong JH, Hwang YS, et al. Clinical research coordinators’ attitude toward risk-based monitoring. Ther Innov Regul Sci 2019; 53: 691–695.
38. Mehra M, Kurpanek K, Petrizzo M, et al. The life cycle and management of protocol deviations. Ther Innov Regul Sci 2014; 48: 762–777.